Biogen's DZP Hits Primary Endpoint in Late-Stage Lupus Trial
BIIB sits 64% above its 52-week low of $151.83.
Summary
Biogen said DZP plus standard of care met the primary endpoint of BICLA response at week 48, with SRI-4 response of 60% versus 41%. That is a clean win on the primary measure with a supportive secondary, the kind of topline that supports a regulatory filing. The readout lands as Biogen's lupus pipeline gains credibility, following the 52-week Phase 2 litifilimab data reported October 2nd showing continued improvement in cutaneous lupus. Biogen is trading near its 52-week high after a Q3 beat on October 28th, so this adds a second late-stage immunology asset to a story the market has already been rewarding.
At the time of this announcement, BIIB was trading at $248.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.7B. The 52-week trading range was $151.83 to $258.78. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.